U.S. buys $26 million of Siga's intravenous treatment for monkeypox
Dow Jones2022-08-10
MW U.S. buys $26 million of Siga's intravenous treatment for monkeypox
Siga Technologies Inc. $(SIGA)$ said Tuesday that the U.S. government is exercising the option to acquire $26 million of the company's intravenous monkeypox treatment and fund a post-marketing study for the therapy. Siga said it plans to deliver these Tpoxx doses in 2023. Siga's stock has soared 203.0% so far this year, while the broader S&P 500 is down 13.5%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments